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Metabonomics is an omics approach to identify and monitor
metabolic characteristics, changes, and phenotypes with
respect to various synergetic factors such as environment,
life style, diet, and potential pathophysiological processes.
Recently, metabonomics has also opened up a possibility
for functional genomics in large genome-wide studies.
Mass spectrometry (MS) and proton nuclear magnetic
resonance (NMR) spectroscopy are the two key experi-
mental technologies in the ﬁeld. Recent advancements are
numerous, and methodologies currently exist that allow for
automated high-throughput experimentation in a very cost-
eﬀective manner. Technical developments have evoked an
increasing number of metabonomics applications in clinical
and epidemiological disciplines to understand the complex
molecular foundations of various diseases. Techniques with
the aim of assessing large numbers of metabolites that are
substrates, intermediates, or products in various metabolic
pathways are particularly relevant in the risk assessment of
metabolic conditions like diabetes and vascular diseases. It
hasalsobeenenvisionedthatmetabonomicsapproachesmay
overtake standard analytical measurements of individual
metabolites and eventually lead to holistic multimetabolic
risk phenotyping in the early detection of high-risk indi-
viduals for various metabolic diseases. Thus, metabonomics
oﬀers potential means to move away from single biomarkers
and thresholds in clinical medicine. And, furthermore, even
though the current medical biomarkers and thresholds are
necessary benchmarks for clinical practice, it will be crucial
to let the future diagnostics to follow from new science.
Good predictions are necessary for eﬀective prevention; an
important step towards this is expected to happen when
complex traits will not anymore be limited by clinical
diagnoses and deﬁnitions but will be handled as multivariate
continuous dimensions. Consequently, clinical and epidemi-
ological metabonomics is likely to be one of the key new
omics areas to assist translational research in the near future.
Here, the Journal of Biomedicine and Biotechnology
presents this special issue, 2011. Although only representing
a small fraction of the contribution of metabonomics to
various biomedical disciplines, the papers presented here
show the increasing potential of metabonomics approaches
to complement clinical and epidemiological research.
To start the special issue, we have ﬁve contributions
that review several aspects of metabonomics research. M. G.
Barderas et al. discuss the concepts of metabolic proﬁling,
ﬁngerprinting, and footprinting focusing on the area of
cardiovascular diseases. E.Silvestriandcoworkersdiscuss the
timely and relevant issue of integrative analyses of related2 Journal of Biomedicine and Biotechnology
omicsdatasetsinordertofurnish newinsightsnotaccessible
through one-dimensional data. Further, I. Kouskoumvekaki
and G. Panagiotou give an extensive up-to-date overview
on the database resources on metabolic pathways and
metabolomes and also summarize the statistical tools often
used for the analysis of metabonomics data. Y. Kim and
S. Milner deal with the challenges related to bioactive food
components in cancer research and prevention. Moreover,
M. Soﬁa and coauthors review the potential use of exhaled
breath condensate as a suitable matrix for NMR-based
metabonomics of airway diseases.
This special issue contains two methodology reports. G.
Kastenm¨ uller and coworkers have developed a freely acces-
sible methodology to facilitate automated and standardized
analysis for quantitative metabolic data, covering the steps
from data acquisition to biological interpretation. M. C.
Mart´ ınez-Bisbal and colleagues, using magnetic resonance
microscopy, present a critical and valuable interpretation on
the high-resolution magic angle spinning data of human
tumor tissues.
The six original research papers in this special issue start
with the paper by J. Willmann et al. who demonstrate the
advantage of combining high-pressure liquid chromatogra-
phy, MS, and NMR spectroscopy in analyzing three diﬀerent
t y p e so fe x t r a c t so fac o m m o nm e m b r a n ec o m p o n e n t
phosphatidylcholine. Then, D. F. Brougham et al. focus on
the use of artiﬁcial neural networks in classifying proton
NMR spectroscopic data recorded on whole-cell culture
samplesoffourdiﬀerentlungcarcinomacelllines,displaying
diﬀerent drug-resistance patterns. In a mouse study, D.
Otter et al. apply MS-based nontargeted urinary metabolite
proﬁling to identify biomarkers of colon inﬂammation. In
another mouse study, J. Zhou et al. provide evidence that
NMR metabonomics may be sensitive enough to detect
small diﬀerences in the composition of maternal plasma
and thus be helpful for identifying biomarkers of birth
defects. Additionally, in low-birth weight and high-birth
w e i g h tp i g l e t sP .M .N i s s e na n dc o w o r k e r sc o m b i n eN M R
and MS to reveal a relationship between birth weight and
plasma inositols, suggesting their potential role in fetal
programming oftype2 diabetes. L.Guo etal.end thisspecial
issue in providing the latest epidemiologic information on
the etiology distribution of neurodevelopmental disabilities
in Chinese, and by demonstrating, on the basis of 8-year
clinical experience, that MS-based pediatric metabonomics
is clinically helpful.
Overall, we hope that this special issue hints at the
rising potential of metabonomics approaches in clinical and
epidemiological research and translational medicine.
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